JPRN-jRCT2051230071招募中2 期
A phase 2, open-label, physician-initiated, multi-institutional study to evaluate the efficacy of induction therapy with MK-3475 and ASG-22CE followed by radiation therapy with MK-3475 in patients with muscle invasive bladder cancer (MIBC) who are unfit for or refuse radical cystectomy. - PEVRAD
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Male/female participants who are at least 18 years of age on the day of signing informed consent and who have a first confirmed diagnosis of MIBC with predominant urothelial histology obtained via a diagnostic or maximal TURBT within 90 days prior to enrollment.
- •Note: Participants with mixed histology are eligible provided the urothelial component is >=50%. Has clinically non-metastatic bladder cancer (N0M0) determined by imaging (CT of the chest and CTU/MRU of abdomen and pelvis), assessed by the site.
- •2.Male participants:
- •A male participant must agree to use a contraception as detailed in Appendix 3 of this protocol and not to donate sperm during the administration of MK-3475 and ASG-22CE and for at least 90 days after the last dose of MK-3475 and for 6 months after ASG-22CE.
- •3.Female participants:
- •A female participant is eligible to participate if she is not pregnant (see Appendix 3), not breastfeeding, and at least one of the following conditions applies:
- •a.) Not a woman of childbearing potential (WOCBP) OR
- •b.) A WOCBP who agrees to follow the contraceptive guidance in Appendix 3 during the treatment period and for at least 120 days after the last dose of MK-3475 and for 6 months after ASG-22CE and RT.
- •4.The participant provides written informed consent for the trial.
- •5.Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Evaluation of ECOG is to be performed within 7 days prior to the first dose of study intervention.
- •6.Demonstrates adequate organ function.All screening laboratory tests should be performed within 10 days prior to the first dose of study intervention.
排除标准
- •1.Has the presence of diffuse CIS (multiple foci [4 or greater] of CIS) throughout the bladder.
- •2.Has the presence of UC at any site outside of the urinary bladder in the previous 2 years except for Ta/T1/CIS of the upper tract if the patient has undergone a complete nephroureterectomy.
- •3.Has the presence of any small cell or neuroendocrine component in the tumor tissue
- •4.Has a known additional malignancy that is progressing or has required active therapy within the past 3 years.
- •Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer or other carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) who have undergone potentially curative therapy are not excluded. Participants with low-risk prostate cancer (T1-T2a, Gleason score =<6, and PSA <10 ng/mL) either treated with definitive intent any time before screening or untreated in active surveillance are not excluded.
- •5.Has limited bladder function with frequency of small amounts of urine (< 30 mL), urinary incontinence, or requires self-catheterization or a permanent indwelling catheter.
- •6.Has a history of radiation therapy to the pelvic region for any reason.
- •7.Has received prior pelvic/local radiation therapy or any antineoplastic treatment for MIBC.
- •Note: Prior treatment for NMIBC with intravesical instillation therapy such as BCG or intravesical chemotherapy is permitted, but must be completed >=28 days before the first dose of the trial drug. Prior systemic treatment received for treatment of NMIBC is not permitted.
- •8.Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).
- •9.Has received prior therapy with an ASG-22CE or other MMAE-containing ADCs.
- •10.Has received a live vaccine or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.
- •11.Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 3 months before the first dose of study intervention.
- •Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.
- •12.A WOCBP who has a positive urine pregnancy test within 72 hours prior to the first dose of study intervention. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- •13.Has uncontrolled diabetes. Uncontrol diabetes is defined as hemoglobin A1c (HbA1c) >=8% or HbA1c 7% to <8% with associated diabetes symptoms (polyuria or polydipsia) that are not otherwise explained.
- •14.Has ongoing sensory or motor neuropathy Grade 2 or higher.
- •15.Has active keratitis or corneal ulceration. Subjects with superficial punctate keratitis are allowed if the disorder is being adequately treated in the opinion of the investigator.
- •16.Has received prior radiotherapy within 2 weeks of start of study intervention or radiation-related toxicities requiring corticosteroids. Note: Two weeks or fewer of palliative radiotherapy for non-CNS disease, with a 1-week washout, is permitted.
- •17.Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosu
研究者
相似试验
招募中
2 期
A Phase II, Open-label, Multicenter, Translational Study for Biomarkers of Eribulin Mesylate: Evaluation of the Utility of Monitoring Epithelial-to-Mesenchymal Transition (EMT) Markers on Tumor Cells in the Malignant Plural Effusion of Patients with Metastatic Breast CancerMetastatic Breast CancerJPRN-UMIN000022362Shizuoka Cancer Center48
进行中（未招募）
1 期
A clinical study to test the efficacy and safety of LDE225 compared to temozolomide in patients with a specific type of brain tumourRelapsed medulloblastoma characterised by Hedgehog (Hh)-pathway activationMedDRA version: 17.0Level: PTClassification code 10066594Term: Medulloblastoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-003066-40-BEovartis Pharma Services AG20
进行中（未招募）
1 期
A clinical study to test the efficacy and safety of LDE225 compared to temozolomide in patients with a specific type of brain tumourRelapsed medulloblastoma characterised by Hedgehog (Hh)-pathway activationMedDRA version: 19.1Level: PTClassification code 10066594Term: Medulloblastoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-003066-40-SEovartis Pharma Services AG20
进行中（未招募）
1 期
A clinical study to test the efficacy and safety of LDE225 in patients with a specific type of brain tumourRelapsed medulloblastoma characterised by Hedgehog (Hh)-pathway activationMedDRA version: 19.0Level: PTClassification code 10066594Term: Medulloblastoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-003066-40-NLovartis Pharma Services AG20
进行中（未招募）
1 期
A clinical study to test the efficacy and safety of LDE225 in patients with a specific type of brain tumourEUCTR2012-003066-40-DEovartis Pharma Services AG20